These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 29763550

  • 1. Selective Inhibition of the Myeloid Src-Family Kinase Fgr Potently Suppresses AML Cell Growth in Vitro and in Vivo.
    Weir MC, Shu ST, Patel RK, Hellwig S, Chen L, Tan L, Gray NS, Smithgall TE.
    ACS Chem Biol; 2018 Jun 15; 13(6):1551-1559. PubMed ID: 29763550
    [Abstract] [Full Text] [Related]

  • 2. Expression of myeloid Src-family kinases is associated with poor prognosis in AML and influences Flt3-ITD kinase inhibitor acquired resistance.
    Patel RK, Weir MC, Shen K, Snyder D, Cooper VS, Smithgall TE.
    PLoS One; 2019 Jun 15; 14(12):e0225887. PubMed ID: 31790499
    [Abstract] [Full Text] [Related]

  • 3. SAR103168: a tyrosine kinase inhibitor with therapeutic potential in myeloid leukemias.
    Bourrié B, Brassard DL, Cosnier-Pucheu S, Zilberstein A, Yu K, Levit M, Morrison JG, Perreaut P, Jegham S, Hilairet S, Bouaboula M, Penarier G, Guiot C, Larroze-Chicot P, Laurent G, Demur C, Casellas P.
    Leuk Lymphoma; 2013 Jul 15; 54(7):1488-99. PubMed ID: 23121564
    [Abstract] [Full Text] [Related]

  • 4. Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth.
    Weir MC, Hellwig S, Tan L, Liu Y, Gray NS, Smithgall TE.
    PLoS One; 2017 Jul 15; 12(7):e0181178. PubMed ID: 28727840
    [Abstract] [Full Text] [Related]

  • 5. Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia.
    Elgamal OA, Mehmood A, Jeon JY, Carmichael B, Lehman A, Orwick SJ, Truxall J, Goettl VM, Wasmuth R, Tran M, Mitchell S, Lapalombella R, Eathiraj S, Schwartz B, Stegmaier K, Baker SD, Hertlein E, Byrd JC.
    J Hematol Oncol; 2020 Jan 28; 13(1):8. PubMed ID: 31992353
    [Abstract] [Full Text] [Related]

  • 6. Combination of midostaurin and ATRA exerts dose-dependent dual effects on acute myeloid leukemia cells with wild type FLT3.
    Lu H, Weng XQ, Sheng Y, Wu J, Xi HM, Cai X.
    BMC Cancer; 2022 Jul 09; 22(1):749. PubMed ID: 35810308
    [Abstract] [Full Text] [Related]

  • 7. ATP-site inhibitors induce unique conformations of the acute myeloid leukemia-associated Src-family kinase, Fgr.
    Du S, Alvarado JJ, Wales TE, Moroco JA, Engen JR, Smithgall TE.
    Structure; 2022 Nov 03; 30(11):1508-1517.e3. PubMed ID: 36115344
    [Abstract] [Full Text] [Related]

  • 8. Aminoisoquinoline benzamides, FLT3 and Src-family kinase inhibitors, potently inhibit proliferation of acute myeloid leukemia cell lines.
    Larocque E, Naganna N, Ma X, Opoku-Temeng C, Carter-Cooper B, Chopra G, Lapidus RG, Sintim HO.
    Future Med Chem; 2017 Jul 03; 9(11):1213-1225. PubMed ID: 28490193
    [Abstract] [Full Text] [Related]

  • 9. The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents.
    Dos Santos C, McDonald T, Ho YW, Liu H, Lin A, Forman SJ, Kuo YH, Bhatia R.
    Blood; 2013 Sep 12; 122(11):1900-13. PubMed ID: 23896410
    [Abstract] [Full Text] [Related]

  • 10. Expression of the c-fgr and hck protein-tyrosine kinases in acute myeloid leukemic blasts is associated with early commitment and differentiation events in the monocytic and granulocytic lineages.
    Willman CL, Stewart CC, Longacre TL, Head DR, Habbersett R, Ziegler SF, Perlmutter RM.
    Blood; 1991 Feb 15; 77(4):726-34. PubMed ID: 1825181
    [Abstract] [Full Text] [Related]

  • 11. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.
    Hu Y, Liu Y, Pelletier S, Buchdunger E, Warmuth M, Fabbro D, Hallek M, Van Etten RA, Li S.
    Nat Genet; 2004 May 15; 36(5):453-61. PubMed ID: 15098032
    [Abstract] [Full Text] [Related]

  • 12. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
    Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, Estrov Z, Quintás-Cardama A, Small D, Cortes J, Andreeff M.
    J Natl Cancer Inst; 2008 Feb 06; 100(3):184-98. PubMed ID: 18230792
    [Abstract] [Full Text] [Related]

  • 13. Src family tyrosine kinases are activated by Flt3 and are involved in the proliferative effects of leukemia-associated Flt3 mutations.
    Robinson LJ, Xue J, Corey SJ.
    Exp Hematol; 2005 Apr 06; 33(4):469-79. PubMed ID: 15781338
    [Abstract] [Full Text] [Related]

  • 14. Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD.
    Okamoto M, Hayakawa F, Miyata Y, Watamoto K, Emi N, Abe A, Kiyoi H, Towatari M, Naoe T.
    Leukemia; 2007 Mar 06; 21(3):403-10. PubMed ID: 17230226
    [Abstract] [Full Text] [Related]

  • 15. Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.
    Garcia JS, Percival ME.
    Drugs Today (Barc); 2017 Oct 06; 53(10):531-543. PubMed ID: 29286055
    [Abstract] [Full Text] [Related]

  • 16. CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia.
    Lopes de Menezes DE, Peng J, Garrett EN, Louie SG, Lee SH, Wiesmann M, Tang Y, Shephard L, Goldbeck C, Oei Y, Ye H, Aukerman SL, Heise C.
    Clin Cancer Res; 2005 Jul 15; 11(14):5281-91. PubMed ID: 16033847
    [Abstract] [Full Text] [Related]

  • 17. Adhesion-dependent degranulation of neutrophils requires the Src family kinases Fgr and Hck.
    Mócsai A, Ligeti E, Lowell CA, Berton G.
    J Immunol; 1999 Jan 15; 162(2):1120-6. PubMed ID: 9916742
    [Abstract] [Full Text] [Related]

  • 18. The Src family kinase Fgr is a transforming oncoprotein that functions independently of SH3-SH2 domain regulation.
    Shen K, Moroco JA, Patel RK, Shi H, Engen JR, Dorman HR, Smithgall TE.
    Sci Signal; 2018 Oct 23; 11(553):. PubMed ID: 30352950
    [Abstract] [Full Text] [Related]

  • 19. The short form of RON is expressed in acute myeloid leukemia and sensitizes leukemic cells to cMET inhibitors.
    Fialin C, Larrue C, Vergez F, Sarry JE, Bertoli S, Mansat-De Mas V, Demur C, Delabesse E, Payrastre B, Manenti S, Roche S, Récher C.
    Leukemia; 2013 Feb 23; 27(2):325-35. PubMed ID: 22902361
    [Abstract] [Full Text] [Related]

  • 20. Role of Src kinases and Syk in Fcgamma receptor-mediated phagocytosis and phagosome-lysosome fusion.
    Majeed M, Caveggion E, Lowell CA, Berton G.
    J Leukoc Biol; 2001 Nov 23; 70(5):801-11. PubMed ID: 11698501
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.